<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Invest New Drugs</journal-id><journal-id journal-id-type="iso-abbrev">Invest New Drugs</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Investigational new drugs</journal-title></journal-title-group><issn pub-type="ppub">0167-6997</issn><issn pub-type="epub">1573-0646</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC6713628</article-id><article-id pub-id-type="pmcid-ver">PMC6713628.1</article-id><article-id pub-id-type="pmcaid">6713628</article-id><article-id pub-id-type="pmcaiid">6713628</article-id><article-id pub-id-type="manuscript-id">NIHMS1522791</article-id><article-id pub-id-type="pmid">30820810</article-id><article-id pub-id-type="doi">10.1007/s10637-019-00744-0</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS1522791</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA1522791</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Population Pharmacokinetic Analysis of AR-67, a Lactone Stable Camptothecin Analogue, in Cancer Patients with Solid Tumors</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Tang</surname><given-names initials="F">Fei</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref rid="FN1" ref-type="author-notes">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tsakalozou</surname><given-names initials="E">Eleftheria</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref rid="FN1" ref-type="author-notes">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Arnold</surname><given-names initials="SM">Susanne M.</given-names></name><xref ref-type="aff" rid="A2">2</xref><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ng</surname><given-names initials="CM">Chee M.</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Leggas</surname><given-names initials="M">Markos</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A3">3</xref></contrib></contrib-group><aff id="A1"><label>1</label>Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, 789 S. Limestone St., Lexington, KY 40536, USA</aff><aff id="A2"><label>2</label>Department of Internal Medicine, Division of Medical Oncology, Markey Cancer Center, University of Kentucky, 800 Rose St., Lexington, KY 40536 Lexington, KY 40536, USA</aff><aff id="A3"><label>3</label>National Cancer Institute Designated Markey Cancer Center, Lexington Kentucky</aff><author-notes><fn fn-type="equal" id="FN1"><label>*</label><p id="P1">Fei Tang and Eleftheria Tsakalozou have contributed equally to this manuscript.</p></fn><corresp id="CR1">Corresponding author: Dr. Markos Leggas, Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, 789 S. Limestone St., Room 323, Lexington, KY 40536, USA. Phone: 859-257-2633, Fax: 859-257-7564. E-mail: <email>mlegg2@email.uky.edu</email></corresp><fn fn-type="COI-statement" id="FN2"><p id="P45">Conflict of Interest</p><p id="P46">S.M. Arnold, and M. Leggas have received research funding from Arno Therapeutics. The authors have no other conflicts of interest to declare.</p></fn></author-notes><pub-date pub-type="epub"><day>28</day><month>2</month><year>2019</year></pub-date><pub-date pub-type="ppub"><month>12</month><year>2019</year></pub-date><volume>37</volume><issue>6</issue><issue-id pub-id-type="pmc-issue-id">341002</issue-id><fpage>1218</fpage><lpage>1230</lpage><pub-history><event event-type="nihms-submitted"><date><day>01</day><month>03</month><year>2019</year></date></event><event event-type="pmc-release"><date><day>01</day><month>12</month><year>2020</year></date></event><event event-type="pmc-live"><date><day>01</day><month>12</month><year>2020</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-06-16 03:25:13.333"><day>16</day><month>06</month><year>2024</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-1522791.pdf"/><abstract id="ABS1"><sec id="S1"><title>Background</title><p id="P2">AR-67 is a novel camptothecin analogue at early stages of drug development. The phase 1 clinical trial in cancer patients with solid tumors was completed and a population pharmacokinetic model (POP PK) was developed to facilitate further development of this investigational agent.</p></sec><sec id="S2"><title>Methods</title><p id="P3">Pharmacokinetic data collected in the phase 1 clinical trial were utilized for the development of a population POP PK by implementing the non-linear mixed effects approach. Patient characteristics at study entry were evaluated as covariates in the model. Subjects (N=26) were treated at nine dosage levels (1.2&#8211;12.4 mg/m<sup>2</sup>/day) on a daily &#215; 5 schedule. Hematological toxicity data were modeled against exposure metrics.</p></sec><sec id="S3"><title>Results</title><p id="P4">A two-compartment POP PK model best described the disposition of AR-67 by fitting a total of 328 PK observations from 25 subjects. Following covariate model selection, age remained as a significant covariate on central volume. The final model provided a good fit for the concentration versus time data and PK parameters were estimated with good precision. Clearance, inter-compartmental clearance, central volume and peripheral volume were estimated to be 32.2 L/h, 28.6 L/h, 6.83 L and 25.0 L, respectively. Finally, exposure-pharmacodynamic analysis using E<sub>max</sub> models showed that plasma drug concentration versus time profiles are better predictors of AR-67-related hematologic toxicity were better predictors of leukopenia and thrombocytopenia, as compared to total dose.</p></sec><sec id="S4"><title>Conclusions</title><p id="P5">A POP PK model was developed to characterize AR-67 pharmacokinetics and identified age as a significant covariate. Exposure PK metrics C<sub>max</sub> and AUC were shown to predict hematological toxicity. Further efforts to identify clinically relevant determinants of AR-67 disposition and effects in a larger patient population are warranted.</p></sec></abstract><kwd-group><kwd>Camptothecins</kwd><kwd>AR-67</kwd><kwd>population pharmacokinetics</kwd><kwd>performance status</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>